Search Results for: 19

Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable Safety Profile and was Well Tolerated at All Dose Levels; A Second Phase 1 Multiple-Ascending Dose Clinical Trial Expected to Commence in Q3 2021 Enrollment in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Proceeding as Planned Reports $74.3 Million of Cash on […]

Updated Agreement Includes Intellectual Property and Technology for Use of SYN-020 Intestinal Alkaline Phosphatase to Inhibit Liver Fibrosis in Select Diseases, Including Nonalcoholic Fatty Liver Disease ROCKVILLE, Md., August 3, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (“GI”) diseases in

Conference Call Scheduled for Thursday, August 5, 2021 at 4:30 p.m. ET ROCKVILLE, Md., July 28, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to

Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 ROCKVILLE, Md., June 29, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas

ROCKVILLE, Md., May 26, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today receipt, on May 25, 2021, of notification from the NYSE American LLC (the “Exchange”) that the Company

Initiated Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients for the Prevention of aGVHD Initiated Phase 1a Single-Ascending-Dose Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase Reports $76.9 Million of Cash on Hand to Fund Clinical Programs Through Proof-of-Concept and Extend Operations into 2023 — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE,

— Conference Call Scheduled for Wednesday, May 5, 2021 at 4:30 p.m. ET — ROCKVILLE, Md., April 28, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in

A Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 Phase 1 Clinical Program Intended to Support Development of SYN-020 in Multiple Indications, Including Treatment of Celiac Disease, Non-Alcoholic Fatty Liver Disease and Age-Related Metabolic and Inflammatory diseases ROCKVILLE, Md., April 1, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging

— Announced Washington University Has Begun Screening Patients for Enrollment in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Reports $72.6M of Cash on Hand to Fund Clinical Programs and Extend Operations into 2023 — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., March 4,